Abstract 2051P
Background
The implementation process, characteristics and objectives of the companion program have been previously reported. Briefly, the program consisted of a web containing an e-PRO questionnaire platform with real time monitoring for early symptom detection and intervention, a communication channel for resolving doubts and educational resources on diagnosis, treatment and adverse events. We aimed to determine the impact of the program in terms of reduction of emergency visits (ERV) and non-planned inpatient admissions (NIA).
Methods
Case-control analysis of patients with gastrointestinal cancer receiving systemic treatment (chemotherapy, immunotherapy, targeted therapy or combinations) at Oncosalud between June 2021 and July 2022. Patients were divided into two cohorts according to enrollment into the companion. Incidence rate (IR), IR ratios (IRR) and 95% confidence intervals were calculated. Time to first ERV and NIA curves since enrollment were constructed using the Kaplan Meier method and log rank test.
Results
In total, 199 patients were included, 97 enrolled into the program (cases). Mean age was 61.4 (±13.2), 50.3% were women and 94% were in ECOG 1-2. Chemotherapy was the most common treatment (88.4%). There were no differences in these characteristics between groups. The mean follow time was of 8.3 and 6.7 months, for cases and controls respectively. A statistically significant reduction in incidence rates was observed for both outcomes. ERV IR was 20.3 ERV per month in controls (95% CI:17.0-24.0) vs 15.1 ERV per month in cases (95%CI:12.6-18.0) which translated into a 25% decrease in ERV (IRR: 0.75 (95%CI:0.58-0.96; p=0.02)). NIA IR was 9.2 NIA per month in controls (95%CI:7.0-11.8) vs 5.9 NIA per month in cases (95%CI:4.4-7.8) which translated into a 35% decrease in NIA (IRR: 0.65 (95%CI:0.44-0.96; p=0.02)). There were no differences in time to first event for both outcomes.
Conclusions
The results demonstrate that e-PRO monitoring within a comprehensive companion program for cancer patients undergoing systemic treatment achieves clinical benefits as it reduces ERV and NIA. Its potential impact on outcomes and costs is being evaluated and will be reported.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncosalud.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06